CHADD has become aware of state and local policies, including legislation and regulations, intended to address the misuse of opioids, but which may have unintended consequences for children and adults prescribed FDA-approved medications to treat attention deficit hyperactivity disorder (ADHD). Read the full statement.

Medication Access Principles: CHADD ascribes to the following principles regarding access to medications indicated to treat attention deficit / hyperactivity disorder (ADHD). Medication is recognized by the scientific community as a primary treatment to effectively reduce the core symptoms of ADHD.[1] Given the stigma associated with ADHD and common misconceptions about treating the disorder, individuals…

The House of Representatives had been preparing to vote on the American Health Care Act (AHCA), which would repeal significant portions of the Affordable Care Act (ACA or “Obamacare”) and replace them with alternative coverage policies. At this time, the House is not moving forward with a vote on the AHCA. Read our full report.

In September 2016, CHADD conducted a survey about health insurance coverage and attention deficit hyperactivity disorder (ADHD) in the United States. More than 1500 people from all 50 states and Washington, D.C. took part in the online survey and answered 15 anonymous questions about their personal experiences seeking access to services and medications for their,…